cytochrome P450 family 2 subfamily C member 9Genealiases: CPC9 · CYP2C · CYP2C10 · CYPIIC9 · P450-2C9 · P450IIC9
Q-omics provides the consensus-scored CYP2C9 profile across patient tissues and cancer cell-line models. CYP2C9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP2C9 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, CYP2C9 RNA expression shows 10,378 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LIHC, and ESCA as cancer lineages where CYP2C9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2C9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2C9 survival associations across molecular data types. CYP2C9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2C9 RNA expression–survival associations across cancer types. High CYP2C9 expression shows unfavorable associations in KIRC, STAD, KICH, LUAD and UVM, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP2C9 RNA expression.
This table summarizes CYP2C9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2C9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2C9 shows lower tumor expression in LIHC, KICH, HNSC and CHOL and higher tumor expression in KIRP and PAAD. The LIHC box plot shows higher CYP2C9 RNA expression in normal versus tumor tissue (log2 FC = −3.522, t-test p < 0.001).
This table shows molecular features associated with CYP2C9 in patient tissues and cancer cell lines. In patient samples, CYP2C9 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2C9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
